Minnesota Oncology

Non-Hodgkin's Lymphoma News

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (July 21, 2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients (May 28, 2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy... Continue Reading

Imbruvica Approved for Mantle Cell Lymphoma (January 23, 2014)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica™ (ibrutinib) for the treatment of patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the... Continue Reading

Link Between Allergies and Blood Cancers in Women (January 1, 2014)

Researchers hare found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading

Reduced-Intensity Stem Cell Transplant Minimizes Effects on Mental Functioning (December 20, 2013)

In contrast to full-intensity stem cell transplants, reduced-intensity stem-cell transplants appear to have little effect on cognitive function. These results were presented at the 2013 Annual Meeting of the American Society of Hematology. Stem cells... Continue Reading

Treatment with Early Stem Cell Transplant Improves Outcomes in Aggressive NHL (November 12, 2013)

Early autologous stem cell transplantation resulted in improved progression-free survival in patients with high-intermediate risk or high-risk disease who experienced a response to induction therapy, according to the results of a study published in the... Continue Reading

Acclaimed Journalist, Author and Cancer Survivor Jamie Reno Joins CancerConnect (September 17, 2013)

September 13, 2013 Press Contact Jamie Reno (858) 467-1070 or Charles Weaver, MD chweaver@omnihealthmedia.com Acclaimed Journalist, Author and Cancer Survivor Jamie Reno Joins CancerConnect Ketchum/Sun Valley, ID – CancerConnect,... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Revlimid Approved for Mantle Cell Lymphoma (July 12, 2013)

The U.S. Food and Drug Administration (FDA) has approved Revlimid® (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included Velcade® (bortezomib). Non-Hodgkin’s... Continue Reading

Latest Non-Hodgkin's Lymphoma News By Stage


Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients (May 28, 2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Rituxan May Prevent Need for Radiation in Mediastinal B-Cell Lymphoma (May 31, 2013)

A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s... Continue Reading

RIT Conditioning with Zevalin Prior to Autologous Transplantation Improves Overall Survival in Patients with DLCL (April 5, 2013)

Radioimmunotherapy conditioning with Zevalin® (ibritumomab tiuxetan) prior to autologous stem cell transplantation in patients with diffuse large cell lymphoma offers a similar relapse incidence to total body irradiation, but has lower toxicity and improved... Continue Reading

Treanda Plus Rituxan is Not Inferior to R-CHOP and R-CVP for advanced NHL (April 2, 2013)

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) was found to be noninferior to the commonly used chemotherapy regimens R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-CVP (rituximab plus cyclophosphamide,... Continue Reading

More Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

Follicular Lymphoma

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients (May 28, 2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (February 8, 2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma (February 1, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients with advanced stage follicular lymphoma, according... Continue Reading

Zevalin Effective in Follicular NHL Refractory to Rituximab (January 24, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results of a study published in the Journal of Clinical... Continue Reading

More Follicular Lymphoma

Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

Treatment with Early Stem Cell Transplant Improves Outcomes in Aggressive NHL (November 12, 2013)

Early autologous stem cell transplantation resulted in improved progression-free survival in patients with high-intermediate risk or high-risk disease who experienced a response to induction therapy, according to the results of a study published in the... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal... Continue Reading

More Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

Indolent/Low Grade Non-Hodgkin's Lymphoma

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (July 21, 2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (February 8, 2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma (February 1, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients with advanced stage follicular lymphoma, according... Continue Reading

Zevalin Effective in Follicular NHL Refractory to Rituximab (January 24, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results of a study published in the Journal of Clinical... Continue Reading

More Indolent/Low Grade Non-Hodgkin's Lymphoma

Mantle Cell Non-Hodgkin's Lymphoma

Imbruvica Approved for Mantle Cell Lymphoma (January 23, 2014)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica™ (ibrutinib) for the treatment of patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Revlimid Approved for Mantle Cell Lymphoma (July 12, 2013)

The U.S. Food and Drug Administration (FDA) has approved Revlimid® (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included Velcade® (bortezomib). Non-Hodgkin’s... Continue Reading

Epigenetic Therapy Promising in Mantle Cell Lymphoma (July 10, 2013)

An epigenetic/immunotherapy regimen of cladribine, Rituxan® (rituximab), and vorinostat produced a 100 percent response rate and complete remissions in 86 percent of patients with newly diagnosed mantle cell lymphoma, according to the results of a study... Continue Reading

R-CHOP Induction Plus Rituxan Maintenance Improves Remission in Older Patients with Mantle Cell Lymphoma (October 23, 2012)

Induction therapy with R-CHOP followed by maintenance with Rituxan® (rituximab) nearly doubled the remission duration in older patients with mantle cell lymphoma, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s... Continue Reading

More Mantle Cell Non-Hodgkin's Lymphoma

Recurrent Non-Hodgkin's Lymphoma

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Adcetris Approved for Two Types of Lymphoma (August 26, 2011)

The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Hodgkin... Continue Reading

Brentuximab Vedotin Effective for Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma (June 16, 2011)

Researchers involved in an international multicenter trial have reported that brentuximab vedotin was effective for treatment of patients with relapsed or refractory anaplastic large cell lymphoma. The details of this study were reported at the 2011 meeting... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal... Continue Reading

More Recurrent Non-Hodgkin's Lymphoma

Screening/Prevention Non-Hodgkin's Lymphoma

Link Between Allergies and Blood Cancers in Women (January 1, 2014)

Researchers hare found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Organ Transplant Recipients Have Increased Cancer Risk (November 9, 2011)

People who have received a solid organ transplant (such as a kidney or liver) are twice as likely as people in the general population to develop cancer. These results were published in the Journal of the American Medical Association. In 2010, more than... Continue Reading

Greater Cancer Risk Among Taller Women (July 28, 2011)

Taller women may have an increased risk of developing certain cancers. Overall, cancer risk increases by 16% for every 4-inch increase in height. These findings were recently reported in Lancet Oncology. Greater insight into height and cancer risk may... Continue Reading

More Screening/Prevention Non-Hodgkin's Lymphoma

T-Cell Non-Hodgkin's Lymphoma

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (May 23, 2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Istodax Active against Refractory Cutaneous T-cell Lymphoma (August 31, 2010)

Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology. Cutaneous T-cell lymphoma (CTCL)... Continue Reading

More T-Cell Non-Hodgkin's Lymphoma